Alpine Global Management’s Grace Therapeutics GRCE Stock Holding History

Alpine Global Management’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-21	Closed	-$3K	–	155
2015 Q3	$3K	Hold	21	–	–	﹤0.01%	84
2015 Q2	$3K	Hold	21	–	–	﹤0.01%	1087
2015 Q1	$5K	Buy	+21	New	+$4.94K	﹤0.01%	308

Other funds holding GRCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

IIM

Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

EWM

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Credential Securities Vancouver $440M AUM 9.75% 1-Year Est. Return

Alpine Global Management's GRCE Position: Q4 2015 in Review

Alpine Global Management sold out of Grace Therapeutics (GRCE) in Q4 2015, closing a stake of 21 shares — an estimated $3K sold.

Alpine Global Management first reported a position in GRCE in Q1 2015 and held it in 3 quarters. The position peaked at $5K in Q1 2015. 12 funds tracked by Wall St. Rank hold GRCE as of Q4 2015.

Alpine Global Management reported no remaining Grace Therapeutics position as of Q4 2015 after selling out during the quarter.
Alpine Global Management sold 21 Grace Therapeutics shares in Q4 2015, an estimated $3K.
Alpine Global Management first reported a position in Grace Therapeutics in Q1 2015 and held it in 3 quarters.
Alpine Global Management's Grace Therapeutics position peaked at $5K in Q1 2015.
12 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2015.

Based on Alpine Global Management's 13F filing for Q4 2015, filed 12 Feb 2016.